Although several key genes such as APC, TP53, and KRAS have been identified to be implicated in the initiation and progression of CRC [2–4], robust biomarkers which could predict risk and clinical outcome of CRC are still required [5]. The gene discussed is KRAS; the disease is colorectal carcinoma.